Literature DB >> 16566060

Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?

Stacy S Shord1, Joseph R Camp.   

Abstract

Few studies describe the administration of Taxol to rats; however, rats are typically used to study the toxicity of new drugs or novel formulations. A dose finding study was conducted to determine a safe dose of Taxol following intravenous administration in rats. Male Sprague-Dawley rats received a bolus of paclitaxel 5-20 mg/kg i.v. Blood was drawn before administration and at the following times after administration: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24 h. Plasma concentrations were determined using high performance liquid chromatography. Two rats received paclitaxel 20 mg/kg and died immediately. Nine rats received paclitaxel 10 mg/kg; seven of these rats died within 12 h and two rats were killed due to moribund conditions. Ten rats received paclitaxel 5 mg/kg with no morbidity. The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h. It is concluded that further pharmacokinetic studies that are rationally designed to include appropriate measures of preclinical toxicity associated with paclitaxel are needed to identify formally the safest dose in rats following intravenous administration; however, these data indicate that male Sprague-Dawley rats can safely receive Taxol in a 5 mg/kg i.v. bolus. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16566060     DOI: 10.1002/bdd.503

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  4 in total

1.  Subharmonic-Aided Pressure Estimation for Monitoring Interstitial Fluid Pressure in Tumors: Calibration and Treatment with Paclitaxel in Breast Cancer Xenografts.

Authors:  Valgerdur G Halldorsdottir; Jaydev K Dave; Andrew Marshall; Anya I Forsberg; Traci B Fox; John R Eisenbrey; Priscilla Machado; Ji-Bin Liu; Daniel A Merton; Flemming Forsberg
Journal:  Ultrasound Med Biol       Date:  2017-04-19       Impact factor: 2.998

2.  Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models.

Authors:  Bharathiraja Subramaniyan; Pallavi Rajaputra; Luong Nguyen; Mengjie Li; Cody J Peer; Jessica Kindrick; William D Figg; Sukyung Woo; Youngjae You
Journal:  Photochem Photobiol       Date:  2020-03-09       Impact factor: 3.421

3.  Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats.

Authors:  Jie Li; Jian Tang; Yingjie Li; Jianqi Yu; Baoshi Zhang; Changhai Yu
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

4.  Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.

Authors:  Yoon-Sok Chung; Ho Chul Kang; Taeyong Lee
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.